156001-68-2

Usage

Uses

Used in Chemical Research:
Methyl 3-cyano-4-hydroxybenzoate is used as a research compound for its unique chemical structure, which may be of interest in the study of aromatic esters and their potential interactions with other molecules.
Used in Pharmaceutical Industry:
Methyl 3-cyano-4-hydroxybenzoate is used as a synthetic intermediate for the production of more complex molecules, potentially including pharmaceuticals. Its specific functional groups may be utilized in the development of new drugs or drug candidates.
Used in Material Science:
Methyl 3-cyano-4-hydroxybenzoate is used as a precursor in the synthesis of advanced materials, such as polymers or composites, where its aromatic and functional groups can contribute to the desired properties of the final product.

InChI:InChI=1/C9H7NO3/c1-13-9(12)6-2-3-8(11)7(4-6)5-10/h2-4,11H,1H3

Upstream product

• 24589-99-9 methyl 3-formyl-4-hydroxybenzoate 
• 773837-37-9 sodium cyanide 
• 15126-06-4 methyl 3-iodo-4-hydroxybenzoate 
• 544-92-3 copper(I) cyanide 
• 584-87-2 3-formyl-4-hydroxybenzoic acid 
• 557-21-1 zinc(II) cyanide 
• 29415-97-2 methyl 3-bromo-4-hydroxybenzoate 
• 143-33-9 sodium cyanide 
• 99-76-3 methyl 4-hydroxylbenzoate 

Downstream Products

• 609804-40-2 2-(4-Methoxycarbonyl-2-cyanophenoxy)-N-(5-chloropyridin-2-yl)acetamide 
• 213598-11-9 methyl 3-cyano-4-[(1-methylethyl)oxy]benzoate 
• 156001-69-3 methyl 3-cyano-4-(((trifluoromethyl)sulfonyl)oxy)benzoate 
• 1192829-78-9 methyl 3-cyano-4-(cyclopropylmethoxy)benzoate 
• 25978-74-9 3-Cyano-4-methoxy-benzoic acid methyl ester 
• 258273-31-3 3-cyano-4-isopropoxybenzoic acid 
• 1072947-68-2 5-[3-(1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl]-2-[(1-methylethyl)oxy]benzonitrile 
• 1312009-22-5 ethyl 4-[6-chloro-5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]butanoate 
• 1312009-23-6 ethyl 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-methyl-1H-indazol-1-yl]butanoate 
• 1312009-61-2 ethyl 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-ethyl-1H-indazol-1-yl]butanoate 
• 1312009-26-9 ethyl 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-(methyloxy)-1H-indazol-1-yl]butanoate 
• 1312009-30-5 5-[3-(1H-indazol-4-yl)-1,2,4-oxadiazol-5-yl]-2-[(1-methylethyl)oxy]benzonitrile 
• 1312009-57-6 4-[6-chloro-5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]butanoic acid 
• 1312009-58-7 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-methyl-1H-indazol-1-yl]butanoic acid 

Relevant academic research and scientific papers

AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.

Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity

Although benzbromarone (BBR) is a conventional, highly potent uricosuric drug, it is not a standard medicine because it causes rare but fatal fulminant hepatitis. We transformed the bis-aryl ketone structure of BBR to generate novel monocyclic amide-linked phenol derivatives that should possess uric acid excretion activity without adverse properties associated with BBR. The derivatives were synthesized and tested for uric acid uptake inhibition (UUI) in two assays using either urate transporter 1-expressing cells or primary human renal proximal tubule epithelial cells. We also evaluated their inhibitory activity against mitochondrial respiration as a critical mitochondrial toxicity parameter. Some derivatives with UUI activity had no mitochondrial toxicity, including compound 3f, which effectively lowered the plasma uric acid level in Cebus apella. Thus, 3f is a promising candidate for further development as a uricosuric agent.

INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF

Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.

OXADIAZOLE MODULATORS OF S1P METHODS OF MAKING AND USING

The invention is directed to Compounds of Formula (I): wherein each variable is defined herein, as well as methods of making and using the compounds as agonists of S1P1 and/or S1P5 for instance for treating graft versus host disease and autoimmune diseases.

Preparation method of 3-cyano-4-isopropoxy methyl benzoate

The invention discloses a preparation method of 3-cyano-4-isopropoxy methyl benzoate. The preparation method comprises the following steps: step I, preparing 3-aldehyde-4-methyl hydroxybenzoate from methyl p-hydroxybenzoate; step II, preparing 3-cyano-4-m

Method for preparing 3-cyano-4-isopropoxybenzoic acid

The invention discloses a method for preparing 3-cyano-4-isopropoxybenzoic acid. A first step, 3-formyl-4-methyl hydroxybenzoate is prepared with methyl parahydroxybenzoate; a second step, 3-cyano-4-methyl hydroxybenzoate is prepared with the 3-formyl-4-methyl hydroxybenzoate; a third step, 3-cyano-4-methyl isopropoxybenzoate is prepared with the 3-cyano-4-methyl hydroxybenzoate; a fourth step, the 3-cyano-4-isopropoxybenzoic acid is prepared with the 3-cyano-4-methyl isopropoxybenzoate. The preparation method of the 3-cyano-4-isopropoxybenzoic acid, which is provided by the invention, has the advantages that 1) the use of the cuprous cyanide of hypertoxic cyanide in a previous process is avoided, and the method is more suitable for industrialization; 2) cyano is prepared by formyl, and the method is high-efficiency and direct, and is suitable for quantity production; 3) all raw materials are cheap and easily obtained, and the cost advantage is obvious.

DEUTERIUM-SUBSTITUTED OXADIAZOLES

Described are deuterated modulators of S1P1 receptors, pharmaceutical compositions thereof, and methods of use thereof.

Chromatography-free entry to substituted salicylonitriles: Mitsunobu-triggered domino reactions of salicylaldoximes

A mild and efficient one-pot procedure is described to transform salicylaldoximes into salicylonitriles using Mitsunobu chemistry. The reactions proceed through the corresponding 1,2-benzisoxazoles that undergo the Kemp elimination in situ to generate the

NOVEL PHENOL DERIVATIVE

Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 1; a pharmaceutically acceptable salt t

OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed.